Medication info
Duroltel 40/5 mg Tablets

Duroltel 40/5 mg Tablets

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablets
Packaging
30 tablets/box [10 tablets/Alu-Alu x 3]
Approval status
Active

MFDS item code 202103317 · Approved 2021.04.22 · Insurance code 660703590

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, reduction of cardiovascular risk · inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medication should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medication is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medication at a dose of 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, reduction of cardiovascular risk · inhibition of atherosclerosis progression

  • Essential hypertension
  • hypercholesterolemia
  • dysbetalipoproteinemia
  • high sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary heart disease
View approved original text

This medication is used for patients who need to take both telmisartan and rosuvastatin simultaneously. Telmisartan primarily reduces the risk of myocardial infarction, stroke, etc., in patients with essential hypertension and those over 55 years old with a high risk of cardiovascular disease. Rosuvastatin lowers blood cholesterol levels in patients with hypercholesterolemia and dyslipidemia, slowing the progression of atherosclerosis and reducing the risk of stroke and myocardial infarction associated with cardiovascular disease. The combination of these two components aids in the management of hypertension and hyperlipidemia and helps prevent cardiovascular diseases.

How to take

Adult dose

This medication should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment is started. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medication is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medication at a dose of 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This medication can seriously harm the fetus if taken during pregnancy, so it should be immediately discontinued if pregnancy is confirmed. Individuals with allergies to this medication or its components, pregnant or potentially pregnant women, and nursing mothers should not take it. It should not be used in patients with severe liver dysfunction or biliary excretion issues, and caution is warranted in cases of liver disease. Patients with muscle disorders or a history of myopathy should be particularly cautious as there is an increased risk of muscle damage when taking this medication. The use of this medication is prohibited in patients with severely reduced renal function, those using certain immunosuppressants, and diabetic patients with impaired kidney function. Elderly patients, those with high potassium levels in the blood, and patients with mildly impaired liver function should be closely observed when using this medication. This medication can cause side effects related to muscles, such as myalgia or muscle weakness, so patients should consult a doctor immediately if symptoms occur. This medication may affect liver function, necessitating regular liver function tests before and during treatment. Because it has blood pressure-lowering effects, dizziness or symptoms of hypotension may occur, so caution is needed when driving or operating machinery. There may be interactions with other medications, so patients must inform their doctor or pharmacist about all medications they are taking, particularly if using potassium-sparing diuretics or certain antibiotics and antifungal agents. Safety and efficacy in children have not been established, and it is not recommended for use in this population. In case of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, and immediate medical attention is necessary. Store in a place out of reach of children, and do not transfer to another container.

Side effects

Elevated ALT, Elevated AST, Elevated serum creatine phosphokinase (CPK), Dizziness, Itching, Dyspepsia, Oral paresthesia, Musculoskeletal rigidity, Acne, Nasopharyngitis, Painful urination, Rhinitis, Oropharyngeal discomfort, Pulmonary disease, Unspecified gastrointestinal disease, Benign gastrointestinal neoplasm, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory loss, Movement disorders, Atherosclerosis, Frequent urination, Tinnitus, Hearing loss, Halitosis, Fatty liver, Upper respiratory infection, Urinary tract infection, Sepsis, Anemia, Thrombocytopenia, Eosinophilia, Hypersensitivity, Anaphylactic reaction, Hyperkalemia, Hypoglycemia, Depression, Insomnia, Anxiety, Syncope, Visual disturbances, Dizziness, Bradycardia, Tachycardia, Hypotension, Orthostatic hypotension, Dyspnea, Abdominal pain, Diarrhea, Abdominal bloating, Vomiting, Abdominal discomfort, Dry mouth, Abnormal liver function, Liver impairment, Increased sweating, Rash, Erythema, Angioedema, Drug rash, Toxic skin rash, Eczema, Urticaria, Myalgia, Low back pain, Muscle cramps, Arthralgia, Limb pain, Tendon pain, Acute renal failure, Chest pain, Weakness, Influenza-like illness, Increased serum creatinine, Increased uric acid, Increased liver enzymes, Elevated serum CK, Decreased hemoglobin, Headache, Facial spasms, Paresthesia, Paralysis, Cough, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Loss of appetite, Arrhythmia, Weakness, Edema, Decreased libido, Facial edema, Alopecia, Rash, Urticaria, Conjunctivitis, Tinnitus, Petechiae, Angioedema, Diabetes, Headache, Dizziness, Constipation, Nausea, Abdominal pain, Pancreatitis, Itching, Myalgia, Myopathy, Rhabdomyolysis, Weakness, Polyneuropathy, Amnesia, Peripheral neuropathy, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Increased transaminases, Stevens-Johnson syndrome, Drug reaction with eosinophilia and systemic symptoms syndrome, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Interstitial lung disease, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Headache, Dizziness, Cough, Palpitations, Fatigue, Nausea, Ineffectiveness, Numbness, Chest discomfort, Syncope, Generalized pain, Muscle cramps, Gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture, and it is safest to store it at a temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablets

Package unit

30 tablets/box [10 tablets/Alu-Alu x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.